Astrazeneca (AZN) Total Current Liabilities (2009 - 2026)

Astrazeneca has reported Total Current Liabilities for 18 years, with the latest figure at -$31.6 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 5.91% year-over-year to -$31.6 billion in Q2 2026; TTM through Jun 2026 was -$31.6 billion, a 5.91% increase from a year earlier, with the FY2025 full-year figure at -$30.6 billion, down 9.87% from the prior year.
• Total Current Liabilities was -$31.6 billion for Q2 2026 at Astrazeneca, up from -$32.6 billion in the prior quarter.
• The five-year high for Total Current Liabilities was -$21.8 billion in Q2 2022, with the low at -$34.1 billion in Q3 2025.
• Average Total Current Liabilities over 5 years is -$28.3 billion, with a median of -$28.6 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities increased 9.31% in 2024, then sank 31.35% in 2025.
• Over 5 years, Total Current Liabilities stood at -$26.3 billion in 2022, then slipped by 16.16% to -$30.5 billion in 2023, then climbed by 8.76% to -$27.9 billion in 2024, then fell by 9.87% to -$30.6 billion in 2025, then slipped by 3.06% to -$31.6 billion in 2026.
• The last three Total Current Liabilities figures came in at -$31.6 billion (Q2 2026), -$32.6 billion (Q1 2026), and -$30.6 billion (Q4 2025), per Business Quant data.